Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Rheumatology in Perspective · Olga Goodman, MD

Glandular care in Sjögren’s: eyes, mouth, salivary function and prevention

A clinical guide to mechanisms, treatment selection, dental prevention, procedures and the limits of the evidence.

Evidence and regulatory details checked: 22 September 2026

Treat four different problems: discomfort, surface injury, loss of secretion and complications

Glandular care in Sjögren’s disease requires several parallel targets. A person may need relief from burning, protection of an injured cornea, prevention of dental decay and evaluation of recurrent gland swelling at the same time. A successful treatment for one target can leave another unchanged. Tear production, ocular staining, pain, salivary flow and caries incidence are therefore separate outcomes, not interchangeable measures of “improvement”.

Before escalating treatment, establish the dominant mechanism and the consequence of missing it. Aqueous deficiency can coexist with meibomian gland dysfunction, allergy, exposure or altered corneal sensation. Oral dryness can reflect autoimmune hypofunction plus medication effects, mouth breathing or candidiasis. Persistent swelling requires its own differential. The framework below combines guidance with explicit appraisal of direct Sjögren studies; it is not a validated treatment algorithm. [G01] [G02] [G03]

Back to contents ↑

A practical baseline assessment that changes management

Record what the patient cannot comfortably do: read, drive, use a screen, sleep, speak, swallow dry food or tolerate dentures. Ask about fluctuating versus sustained loss of vision, contact lenses, previous ocular surgery, glaucoma, recurrent infection, new caries, weight loss and gland swelling. Reconcile prescription medicines, over-the-counter antihistamines, supplements, topical preparations and inhalers. Avoid attributing all dryness to autoimmune activity.

The ophthalmic examination should characterize tear quantity and stability, corneal and conjunctival staining, eyelid margins, meibomian glands, blink and lid closure. Assess corneal sensitivity when symptoms and signs diverge or healing is impaired. Oral assessment should document mucosal integrity, saliva pooling and flow where useful, dentition and restorations, root exposure, periodontal disease, candidiasis and major-gland findings. Test conditions and concomitant treatment matter when comparing serial results. [G03] [G04] [G05]

FindingWhat it informsWhat it cannot establish alone
Low Schirmer resultAqueous tear deficiencyThe cause of pain, total Sjögren activity or a universal treatment choice
Short tear break-up timeTear-film instabilityPurely evaporative disease; aqueous and mucin abnormalities can contribute
Surface stainingEpithelial injury and its distributionThe intensity of the patient's symptoms
Low unstimulated saliva flowBasal secretory impairment and preventive needsIrreversible loss of all gland function
New cervical or root cariesFailure of the current prevention planPoor motivation or hygiene as the sole cause

Back to contents ↑

Ocular lubrication: formulation, exposure and technique

Choose a preparation the patient can use consistently. More viscous drops, gels or ointments may persist longer but blur vision; nighttime and daytime requirements differ. Lipid-containing products may help an evaporative component. Preservative-free preparations become especially relevant with frequent dosing, substantial surface disease or intolerance. EULAR uses four or more daily applications as a practical threshold for preferring preservative-free tears. This is not a biological boundary below which every preservative is harmless. [G01] [G03]

Ask the patient to demonstrate instillation and describe storage, opening dates and use with other drops. A multidose preservative-free bottle and a single-use vial have different handling requirements. Avoid tip contact with the eye or skin and follow the actual product's instructions. Lubrication reduces friction and exposure; it does not establish control of the underlying systemic autoimmune process. A rising need for drops warrants reassessment rather than indefinite multiplication of brands.

Back to contents ↑

Meibomian glands, exposure and environmental contributors

Sjögren-associated aqueous deficiency does not exclude evaporative disease. Examine obstructed meibomian orifices, secretion quality, rosacea, incomplete blinking and lagophthalmos. Gentle lid care and appropriately warm compresses can be useful when the target is meibomian dysfunction. Excessive heat or vigorous massage can injure sensitive skin and tissue. Moisture chambers, adjustment of direct airflow and deliberate complete blinking can reduce exposure without replacing treatment of epithelial injury. [G03] [G04]

Office procedures need phenotype selection. A Chinese randomized study enrolled 55 patients with Sjögren-related dry eye to assess intense pulsed light with gland expression; it supplies direct Sjögren evidence, although a small study of a combined intervention cannot establish durable superiority of every IPL protocol or device. It is inappropriate to describe IPL either as wholly unstudied in Sjögren’s or as proven restoration of lacrimal-gland function. Discuss eye protection, skin suitability, treatment burden and cost. [G16]

Back to contents ↑

Topical anti-inflammatory treatment: define the target and review date

Persistent inflammatory surface disease may require prescription treatment beyond lubrication. Ciclosporin formulations and lifitegrast are not interchangeable by concentration, vehicle, indication, tolerability or dosing. Discuss delayed benefit, early burning and the need for a tolerable background regimen. The question at review is whether surface health, function and symptoms have improved enough to justify continuing, not simply whether the medicine was prescribed. [G06] [G07] [G08]

Topical corticosteroids can be useful for selected inflammatory episodes under ophthalmic supervision, sometimes while longer-term therapy takes effect. They require a defined course and attention to infection, intraocular pressure and cataract risk. Patients should not repeatedly restart old steroid drops for an undiagnosed red eye. EULAR also cautions against prolonged topical NSAIDs because of corneal toxicity. Pain relief alone is insufficient evidence that the epithelium is safe. [G01] [G03]

Back to contents ↑

What regional drug approvals actually mean

The table describes selected established regulatory indications or regional research, checked on 22 September 2026. It is not an inventory of local pharmacy stock or insurance coverage. A dry-eye indication is not approval to modify systemic Sjögren’s disease. A new mechanism is not evidence that it outperforms all existing options.

Product or approachVerified settingInterpretation for Sjögren care
Lifitegrast 5% (Xiidra)US label: signs and symptoms of dry-eye diseaseTopical LFA-1 antagonist; irritation, dysgeusia and transient visual disturbance can affect adherence. [G06]
Ciclosporin (Ikervis)EU: severe keratitis in adults with dry eye inadequately improved by tear substitutesA specific keratitis indication; not a generic claim about every ciclosporin formulation. [G07]
Ciclosporin (Vevizye)EU authorization 19 September 2024; moderate to severe dry eye inadequately improved by tear substitutesBroader dry-eye indication than Ikervis; use its own product information. [G08]
Perfluorohexyloctane (Miebo)US dry-eye indication; pivotal population had signs of meibomian gland dysfunctionTargets tear evaporation. Transfer to a predominantly aqueous-deficient Sjögren phenotype requires judgment. [G09]
Varenicline nasal spray (Tyrvaya)US dry-eye indicationStimulates a neural tear pathway; route is nasal, not ocular. Sneezing and nasal/throat effects differ from drop intolerance. [G10]
Acoltremon 0.003% (Tryptyr)FDA approval 28 May 2025 for dry-eye diseaseTRPM8 agonist. Schirmer response is not proof of gland regeneration or systemic benefit. Instillation pain is common. [G11]
Diquafosol and rebamipide ophthalmic preparationsImportant Asian research and practice options; Japanese and Korean trialsEvidence must be read by formulation and population; a general dry-eye trial is not automatically a Sjögren trial. Availability and authorization need a local check. [G17] [G18]

Back to contents ↑

Reading a modern dry-eye trial without overstating the result

FDA's acoltremon efficacy assessment included COMET-2 and COMET-3, with 931 participants overall. The proportion achieving a rise of at least 10 mm in the specified Schirmer assessment at day 14 was 42.6% versus 8.2% in COMET-2 and 53.2% versus 14.4% in COMET-3. The endpoint compares a pre-drop baseline measure with a post-drop day-14 measure; it should not be described as permanent recovery of basal secretion. Instillation-site pain occurred in roughly half of treated participants in the pooled safety data. [G11]

These are meaningful tear-production data for the studied population. They do not establish an effect on dental outcomes, immune-mediated gland damage or systemic organ disease. When considering a patient with Sjögren’s, ask whether the study population represents their degree of secretory failure, whether symptomatic and functional benefits are plausible, and whether adverse effects and treatment burden are acceptable. Do not infer a treatment hierarchy from separate placebo-controlled trials.

Back to contents ↑

Punctal occlusion: tear retention is a selected intervention

Punctal plugs reduce tear drainage. Consider the surface inflammatory state, infection, baseline tearing and tear clearance before placement. Patients should understand possible epiphora, irritation, extrusion, migration and canalicular infection, as well as the need to check persistent symptoms after a procedure. Temporary occlusion can help assess tolerability; permanent cautery is a separate decision. [G01] [G03]

Published evidence does not justify promising a uniform response or placing plugs solely because Sjögren’s is diagnosed. Persistently low tear volume after other measures may support a trial, but plugs do not repair secretory tissue. A person whose main problem is neuropathic pain may obtain little relief despite better tear retention.

Back to contents ↑

Serum and platelet-derived drops: useful options with nonuniform evidence

Autologous serum and platelet-derived preparations may be considered for refractory surface disease or impaired epithelial healing by a specialist service. Products vary in concentration, processing, cellular content, storage and administration. Specify which preparation is being discussed; “PRP” does not describe a standardized eye-drop product. Aseptic preparation, traceability and cold-chain instructions are part of treatment, not optional details. [G01] [G15]

A Korean randomized study of primary Sjögren dry eye reported improvement in staining and tear-film stability with serum and PRP, without a significant difference between the groups; Schirmer and symptom questionnaire scores did not significantly improve. The small sample, short follow-up and absence of a placebo comparison constrain the inference. Similar results in two active groups do not prove either universal equivalence or PRP superiority. These drops support the ocular surface; they are not evidence that lacrimal glands have regenerated. [G15]

Back to contents ↑

Scleral lenses and advanced surface protection

Specialist-fitted scleral lenses provide a fluid reservoir over the cornea and can improve surface protection and functional vision in selected severe disease. Fitting, handling ability, cost, follow-up and access to sterile filling solutions determine feasibility. They are medical devices requiring cleaning and disinfection, not a substitute for ongoing corneal examination. Routine sleeping in lenses and exposure to tap water increase avoidable risk. [G03] [G04]

Persistent epithelial defects may need additional corneal measures, including amniotic membrane or other specialist treatment selected for the lesion. Severe corneal thinning, ulceration or suspected melt is an urgent ophthalmic problem. Systemic rheumatologic involvement may become relevant in destructive inflammatory disease; that situation is distinct from prescribing immunosuppression solely to reduce ordinary dryness.

Back to contents ↑

Neuropathic pain, reduced sensation and symptoms–signs discordance

Severe burning or wind/light sensitivity with modest staining should prompt a broader assessment rather than dismissal. Ocular surface disease and altered peripheral or central pain processing can coexist. Conversely, reduced corneal sensation can make substantial epithelial injury surprisingly painless. Symptom intensity alone cannot determine whether the cornea is safe. [G03] [G04]

Review surface findings, sensation, treatment toxicity, migraine and other pain contributors. A corneal specialist may use additional tests to define a peripheral component; no single office maneuver fully excludes central sensitization. Establish a shared plan across ophthalmology, rheumatology and pain/neurology services when indicated. Repeatedly adding preserved drops or procedures without re-evaluating the mechanism can increase treatment burden without improving function.

Back to contents ↑

Oral dryness: distinguish xerostomia, hypofunction and structural complications

Xerostomia is a sensation; salivary hypofunction is a measured reduction in secretion. Both matter. Saliva lubricates tissue, buffers acids, clears substrates and supports mineral balance at tooth surfaces. Water can make swallowing easier but cannot reproduce these functions. A preventive dental plan remains necessary even when comfort improves. [G05]

Review drying drugs with their prescribers, hydration, mouth breathing, reflux, diabetes and coexisting mucosal disease. Unstimulated and stimulated flow can answer different questions about basal secretion and residual reserve. Neither a low flow value nor a gland ultrasound appearance alone determines the chance of symptomatic benefit from every intervention. Document the clinical consequences and re-measure only when the result will change management.

Back to contents ↑

Daily oral care and saliva replacement

Neutral-pH saliva substitutes, gels or sprays can be chosen by tolerability, denture use and day/night needs. Sugar-free chewing gum or lozenges may stimulate residual secretion; avoid using repeated acidic sweets, lemon or sugary drinks as the main dryness remedy. A product can be sugar-free yet acidic. Patients with jaw pain, swallowing difficulty or aspiration risk need adapted choices. [G02] [G05]

Support gentle twice-daily brushing with fluoride toothpaste and interdental cleaning adapted to dexterity and discomfort. Discuss a practical diet and the frequency of sugar/acid exposures rather than imposing broad food exclusions without a reason. Address lip fissuring, traumatic dentures and overnight mouth breathing. A manageable routine has a better chance of success than an unaffordable list of specialized products.

Back to contents ↑

Caries prevention: strong clinical priority, uneven Sjögren-specific trial evidence

The Sjögren Foundation oral guideline strongly recommends topical fluoride. The route and intensity should follow caries risk, existing lesions, root exposure, age and ability to use the product safely. For selected adults at high risk, prescription-strength toothpaste or gel and professionally applied fluoride may be appropriate. A high-fluoride product is not a universal pediatric recommendation, and fluoride rinses should not simply displace brushing. [G02] [G19]

A Hong Kong trial recruited 85 patients and had 78 complete 24 months of quarterly fluoride varnish or placebo. The primary comparisons in new caries did not establish a statistically significant benefit; the investigators concluded the results could neither support nor refute that varnish schedule. This inconclusive, under-recruited trial does not show that fluoride prevention is ineffective, nor should it be advertised as definitive proof of a large varnish benefit. Separate the overall prevention recommendation from certainty about a particular regimen. [G20]

Back to contents ↑

Chlorhexidine, remineralizing agents and dental rehabilitation

Chlorhexidine may have a selected adjunctive role in a high-caries-risk plan; it is not a saliva replacement or a routine lifelong requirement. Staining, taste effects and irritation can limit use. Nonfluoride remineralizing agents are adjuncts, not established replacements for fluoride. Xylitol-containing products may support a sugar-free stimulation strategy, but comfortable chewing and increased flow should not be represented as proven prevention of every dental complication. [G02]

Dental disease still requires lesion-specific treatment. Distinguish caries, erosive tooth wear and periodontal inflammation: they have overlapping but different drivers. Assess denture fit, mucosal tolerance and access for cleaning around restorations. Sjögren’s is not by itself an automatic exclusion from dental implants; prognosis depends on local tissue, infection control, maintenance and the wider clinical context. Individual outcome promises cannot be extracted from small observational implant series. [G21]

Back to contents ↑

Pilocarpine and cevimeline: supervised therapeutic trials

Oral muscarinic agonists can improve dry-mouth symptoms and secretion in some patients. Agree on a concrete target—less nocturnal drinking, easier speaking or eating—and a review of benefit and tolerability. They stimulate remaining secretory pathways; a response does not demonstrate immune remission. The US Sjögren label for pilocarpine specifies 5 mg four times daily; cevimeline specifies 30 mg three times daily. These are label reference doses, not an individualized prescription. Dose selection or titration may differ with tolerability and local guidance. [G12] [G13]

Both labels contraindicate use in uncontrolled asthma and conditions where miosis is undesirable, including acute iritis and narrow-angle glaucoma. Cardiopulmonary disease, relevant drug interactions, pregnancy/lactation and hepatic considerations require review. Sweating, nausea, diarrhea, urinary frequency and visual effects can undermine usefulness. Excessive sweating can cause dehydration. Do not respond to poor benefit by automatically escalating beyond the evidence. [G12] [G13]

The pivotal programs support symptom benefit but do not establish prevention of lymphoma, dental decay or progression of systemic disease. In a 75-patient cevimeline trial, higher-dose treatment caused more gastrointestinal intolerance; “more” is not necessarily a better clinical strategy. Residual function and a patient's priorities matter, but there is no universally validated flow threshold that guarantees an individual response. [G14]

Formulation update · 11 November 2026. FDA approved EVOXAC oral solution for adult Sjögren-related dry-mouth symptoms on 15 October 2026. The concentration is 30 mg/5 mL; the labeled dose is 5 mL three times daily with a glass of water. Use a calibrated measuring device. This formulation may ease administration when capsules are difficult to swallow; it does not change the systemic treatment goal or remove cholinergic contraindications. US availability was expected by year-end 2026. FDA approval · Prescribing information · Availability announcement

Back to contents ↑

Burning mouth, candidiasis, ulcers and dysphagia

Examine before attributing oral burning to autoimmune activity. Candidiasis, mechanical trauma, reflux, contact irritation, nutritional deficiency and neuropathic burning may require different management. White plaques are only one possible candidal presentation; persistent erythema or denture-associated soreness may also matter. Treat confirmed or clinically supported infection with an appropriate regimen and address prosthesis hygiene and predisposing factors. Repeated empirical antifungal treatment without reassessment can delay the correct diagnosis. [G05] [G21]

A nonhealing ulcer, focal induration, progressive swallowing difficulty, weight loss, painful swallowing or recurrent aspiration needs targeted evaluation. Dry food may be harder to swallow because lubrication is reduced, but not every dysphagia symptom is salivary. Coordinate oral medicine, dentistry, ENT or swallowing/gastrointestinal assessment according to the pattern. A patient unable to maintain fluid intake needs prompt clinical attention.

Back to contents ↑

Painful or persistent gland enlargement: do not use one pathway for every presentation

Meal-related episodic swelling raises the possibility of obstruction. Pain, fever, erythema or purulent duct discharge raise concern for acute infection. Persistent asymmetry, a discrete mass, progressive enlargement or associated lymphadenopathy requires evaluation for lymphoproliferative or other structural disease. These are patterns that guide assessment, not diagnostic rules. Ultrasound can help characterize the gland and select further sampling where appropriate. [G22]

Do not reassure a persistent focal lesion simply because bilateral gland changes are common in Sjögren’s. Equally, gland swelling is not synonymous with lymphoma. Referral and tissue strategy should be driven by the lesion and the clinical context. Rapidly increasing neck swelling, difficulty breathing or inability to swallow requires urgent assessment. The module's systemic atlas provides the fuller lymphoma-risk and biopsy discussion.

Back to contents ↑

Sialendoscopy: promising procedural evidence with a defined scope

A Dutch randomized study assigned 45 patients to no irrigation, saline irrigation or saline followed by triamcinolone during sialendoscopy. Longitudinal salivary and symptom outcomes favored intervention, with some improvement persisting to 60 weeks. This supports a possible role in selected patients with residual secretion and ductal disease; it does not demonstrate regeneration of gland tissue or reliable benefit for all patients with severe hypofunction. [G23]

Selection, anesthesia, duct access, procedural discomfort, infection and stenosis risks belong in the discussion. The small study cannot settle which irrigation protocol is best, how often to repeat treatment or whether long-term dental outcomes improve. Referral to an experienced salivary-gland service is more appropriate than presenting the procedure as a routine next step for every dry mouth.

Back to contents ↑

Why systemic therapy and local gland care remain separate decisions

In EULAR guidance, hydroxychloroquine, conventional immunosuppressants or rituximab are not recommended solely to treat ocular or oral dryness on the basis of the evidence considered. That does not negate their role for a separate inflammatory organ indication. A patient receiving effective systemic therapy may still require an extensive local prevention plan. Conversely, persistent dryness does not by itself prove that systemic treatment has failed. [G01]

Future trials may change the evidence for selected disease stages and phenotypes. When reading a positive systemic trial, inspect glandular outcomes, baseline residual function and the actual endpoint. Improvement in a composite activity score cannot be converted into a claim of restored saliva, reduced caries or relief of ocular pain without supporting data.

Back to contents ↑

Supplements and emerging glandular therapies: keep the claim proportional

The US DREAM trial found no advantage of high-dose omega-3 supplementation over its olive-oil comparator for the main dry-eye outcomes in the studied population. This undermines routine claims of a large, dependable benefit; it does not mean every nutritional question has been answered. Diet quality and correction of a documented deficiency are different decisions from selling a supplement as treatment for Sjögren’s. [G24]

SA001, an oral rebamipide prodrug studied in South Korea, has a published 2026 phase 2a trial in 28 women with primary Sjögren’s. The investigators explicitly describe efficacy findings as exploratory. It belongs in the investigational discussion, not in a list of proven replacements for secretagogues or immunomodulators. Small early trials cannot establish durable gland recovery, uncommon harms or effectiveness across sexes and phenotypes. [G25]

Regenerative concepts—cell therapies, organoids, tissue engineering and restoration of epithelial–neural signaling—require evidence that a proposed mechanism produces durable, clinically useful secretion in humans. A biomarker change, animal experiment or improvement after radiation injury is not automatically transferable to autoimmune gland disease. For any commercial regeneration claim, ask for the registered study, comparator, patient population, functional endpoint, adverse events and follow-up. This is an appraisal framework, not an endorsement of an unproven procedure.

Back to contents ↑

Monitor outcomes that matter and make responsibilities explicit
DomainUseful follow-up question
Ocular comfort and functionCan the patient read, drive and work more comfortably, with an acceptable drop burden?
Ocular safetyIs staining or epithelial injury improving? Are pressure or infection checks needed for the chosen treatment?
Oral functionIs eating, speaking or sleep easier without unacceptable adverse effects?
Dental preventionHave new lesions appeared? Is fluoride delivery, diet, recall frequency or restorative care adequate?
Gland enlargementHas the focal finding resolved, persisted or progressed, and who owns follow-up?

Give the patient a written plan identifying the ophthalmic, dental and rheumatologic priorities, who will review each, and what should trigger earlier assessment. Review intervals should follow lesion severity and treatment risk, not a single calendar rule for everyone. Pain, photophobia or a meaningful new reduction in vision requires prompt eye assessment; rapid gland swelling with fever, swallowing difficulty or systemic illness requires prompt medical review. An intervention is useful when its clinical benefit exceeds its adverse effects, burden and cost for this patient.

Back to contents ↑

Sources and evidence

The source list distinguishes clinical guidance, direct Sjögren trials, general dry-eye studies and regulatory labels. Regulatory authorization does not guarantee local availability or reimbursement.

  1. [G01] EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies. 2019 online / 2020 issue. DOI: 10.1136/annrheumdis-2019-216114. https://revmatologicka-spolecnost.cz/data/files/page/703/SS-lecba-2019.pdf
  2. [G02] Sjögren’s Foundation. Clinical practice guidelines: oral management and caries prevention. https://sjogrens.org/sites/default/files/inline-files/SF_PCG-Oral_0.pdf
  3. [G03] Sjögren’s Foundation. Ocular clinical practice guideline summary (guideline published 2015; file distributed in 2022). https://sjogrens.org/sites/default/files/inline-files/SF_CPG-Ocular_2022_0.pdf
  4. [G04] Aqueous-deficient dry eye disease: preferred practice pattern guidelines on clinical approach, diagnosis, and management. Indian Journal of Ophthalmology. 2023;71:1332–1347. https://pubmed.ncbi.nlm.nih.gov/37026265/
  5. [G05] American Dental Association. Xerostomia (Dry Mouth). https://www.ada.org/resources/ada-library/oral-health-topics/xerostomia
  6. [G06] DailyMed. Xiidra (lifitegrast) prescribing information. US label. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8589d376-ac10-4ddb-9c53-2e0c8d5675c4
  7. [G07] European Medicines Agency. Ikervis (ciclosporin): authorized indication and product information. https://www.ema.europa.eu/en/medicines/human/EPAR/ikervis
  8. [G08] European Medicines Agency. Vevizye (ciclosporin): authorized indication and product information. EU authorization 19 September 2024. https://www.ema.europa.eu/en/medicines/human/EPAR/vevizye
  9. [G09] DailyMed. Miebo (perfluorohexyloctane) prescribing information; GOBI and MOJAVE populations. https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6b283c02-7df4-4c00-951b-555cddffe77c&type=display
  10. [G10] DailyMed. Tyrvaya (varenicline solution) nasal spray prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=014c93dc-5737-479c-a9f0-aaadac1ac298
  11. [G11] US FDA. Drug Trials Snapshot: Tryptyr (acoltremon). Approval 28 May 2025; COMET program. https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshot-tryptyr
  12. [G12] DailyMed. Salagen (pilocarpine hydrochloride) prescribing information. Updated 5 December 2024. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=62eda83d-d043-4c7e-8fcf-75d05efbf35b
  13. [G13] DailyMed. Cevimeline hydrochloride capsules prescribing information. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d7432a48-1142-431e-997f-8419dc724824
  14. [G14] Fife RS et al. Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial. Archives of Internal Medicine. 2002. DOI: 10.1001/archinte.162.11.1293. https://pubmed.ncbi.nlm.nih.gov/12038948/
  15. [G15] Kang MJ et al. Platelet-rich plasma and autologous-serum eye drops for dry eye in primary Sjögren’s: randomized trial. Scientific Reports. 2023;13:19279. DOI: 10.1038/s41598-023-46671-2. https://www.nature.com/articles/s41598-023-46671-2
  16. [G16] Therapeutic effect of intense pulsed light in patients with Sjögren’s syndrome related dry eye. Journal of Clinical Medicine. 2022;11:1377. DOI: 10.3390/jcm11051377. https://www.mdpi.com/2077-0383/11/5/1377
  17. [G17] Randomized multicenter phase 3 study comparing 2% rebamipide with 0.1% sodium hyaluronate in dry eye. Ophthalmology. 2013. https://pubmed.ncbi.nlm.nih.gov/23490326/
  18. [G18] Comparing two mucin secretagogues for dry eye disease: prospective randomized crossover trial. 2024. Diquafosol and rebamipide; general dry-eye population. https://pubmed.ncbi.nlm.nih.gov/38858411/
  19. [G19] American Dental Association. Fluoride: topical agents and systemic supplements. https://www.ada.org/resources/ada-library/oral-health-topics/fluoride-topical-and-systemic-supplements
  20. [G20] Xin W et al. Randomized clinical trial of fluoride varnish in preventing dental caries of Sjögren’s syndrome patients. BMC Oral Health. 2016. DOI: 10.1186/s12903-016-0296-7. https://link.springer.com/article/10.1186/s12903-016-0296-7
  21. [G21] American Dental Association. Sjögren Disease: oral manifestations, management and dental considerations. https://www.ada.org/resources/ada-library/oral-health-topics/sjogren-disease/
  22. [G22] British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease. Online 2024 / issue 2025. DOI: 10.1093/rheumatology/keae152. https://doi.org/10.1093/rheumatology/keae152
  23. [G23] Karagozoglu KH et al. Sialendoscopy, salivary flow and xerostomia: randomized study with 60-week follow-up. Rheumatology. 2021;60:1353–1363. DOI: 10.1093/rheumatology/keaa284. Author institutional abstract. https://research.vu.nl/en/publications/sialendoscopy-increases-saliva-secretion-and-reduces-xerostomia-u/
  24. [G24] National Eye Institute. DREAM randomized trial: omega-3 supplements and dry-eye outcomes. 2018. https://www.nei.nih.gov/research-and-training/research-news/omega-3s-fish-oil-supplements-no-better-placebo-dry-eye
  25. [G25] Efficacy and safety of SA001 in primary Sjögren’s syndrome: randomized double-blind placebo-controlled exploratory phase 2a trial. Pharmaceuticals. 2026;19:189. DOI: 10.3390/ph19010189. https://www.mdpi.com/1424-8247/19/1/189
  26. [G26] TFOS DEWS III: Management and Therapy. American Journal of Ophthalmology. 2025;279:289–386. International dry-eye report. https://pubmed.ncbi.nlm.nih.gov/40467022/
  27. [G27] Japan College of Rheumatology. Clinical practice guideline for Sjögren syndrome, 2025. Official publication information; Japanese. https://www.ryumachi-jp.com/publish/others/ss2025/

Sjögren’s module ↑

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Dry eyesDry mouthSalivary glandsSjögren disease